
Claims


1. A compound of formula (I):



(I)

wherein:
X is CR_1 or N;
Y is CH, C or N;
R_1 is hydrogen, C_{1-6}alkoxy or C_{1-6}alkyl;
R_2 is hydrogen, C_{1-6}alkoxy, halo, -C(O)C_{1-6}alkyl, CN, Halo-C_{1-6}alkyl or C(O)NR_4R_5;
R_3 is hydrogen or C_{1-6}alkoxy;
R_4 is hydrogen or C_{1-6}alkyl:
R_5 is hydrogen or C_{1-6}alkyl and
m and n are integers each independently selected from 1 and 2; or
a salt thereof.

2. A compound according to claim 1, wherein the compound is a compound of formula (Ia):



(Ia)

wherein:
X is CR_1 or N;
Y is CH, C or N;
R_1 is hydrogen, C_{1-6}alkoxy or C_{1-6}alkyl;
R_2 is hydrogen, C_{1-6}alkoxy, halo or -C(O)C_{1-6}alkyl; and
m and n are integers each independently selected from 1 and 2; or
a salt thereof.

3. A compound or a salt thereof according to claim 1 or claim 2 wherein X is CR_1.

4. A compound or a salt thereof according to claim 3 wherein R_1 is methyl, methoxy or hydrogen.

5. A compound or a salt thereof according to any one of claims 1 to 4 wherein R_2 is hydrogen, methoxy, fluoro or $-C(O)CH_3$.

6. A compound or a salt thereof according to claim 5 wherein R_2 is hydrogen, methoxy or $-C(O)CH_3$.

7. A compound or salt thereof according to any one of claims 1 to 6 wherein R_3 is hydrogen or C_{1-6}alkoxy.

8. A compound or salt thereof according to claim 7 wherein R_3 is hydrogen, or methoxy.

9. A compound or salt thereof according to any one of claims 1 to 8 wherein R_4 is hydrogen or C_{1-6}alkyl.

10. A compound or salt thereof according to any one of claims 1 to 9 wherein R_5 is hydrogen or C_{1-6}alkyl.

11. A compound or a salt thereof according to any one of claims 1 to 10 wherein m is 2 and n is 1 or 2.

12. A compound or a salt thereof according to claim 11 wherein m and n are both 2.

13. A compound which is selected from:
7-(3-{[(4-methyl-2-pyridinyl)methyl]oxy}-2-pyridinyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
7-(2-(methyloxy)-6-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
7-(4-(methyloxy)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
1-[4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)phenyl]ethanone;
7-(6-methyl-3-{[(4-methyl-2-pyridinyl)methyl]oxy}-2-pyridinyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
1-[4-[(2-pyrazinylmethyl)oxy]-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)phenyl]ethanone;

7-(5-fluoro-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
7-(5-methyl-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
7-(2-(methyloxy)-6-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
7-(5-(ethyloxy)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
7-(4-(methyloxy)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(1,2,3,4-tetrahydro-7-isoquinolinyl)benzonitrile;
7-[2-{[(4-methyl-2-pyridinyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydroisoquinoline;
7-(5-(methyloxy)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
7-(5-(1,1-dimethylethyl)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
N-methyl-4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzamide;
4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzamide;
N,N-dimethyl-4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(1,2,3,4-tetrahydro-7-isoquinolinyl)benzamide;
4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(1,2,3,4-tetrahydro-7-isoquinolinyl)benzamide;

7-(2,3-bis(methyloxy)-6-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
7-(2,3-bis(methyloxy)-6-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
7-[2-({[4-(methyloxy)-2-pyridinyl]methyl}oxy)phenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine;
1-[4-[(2-pyridinylmethyl)oxy]-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)phenyl]ethanone, trifluoroacetate;
7-{6-methyl-3-[(2-pyrazinylmethyl)oxy]-2-pyridinyl}-2,3,4,5-tetrahydro-1H-3-benzazepine, trifluoroacetate ;
7-(6-methyl-3-{[(4-methyl-2-pyridinyl)methyl]oxy}-2-pyridinyl)-2,3,4,5-tetrahydro-1H-3-benzazepine, trifluoroacetate;
7-{5-(methyloxy)-2-[(2-pyrazinylmethyl)oxy]phenyl}-2,3,4,5-tetrahydro-1H-3-benzazepine, trifluoroacetate ;
7-[5-(methyloxy)-2-({[4-(methyloxy)-2-pyridinyl]methyl}oxy)phenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine;
7-(5-(methyloxy)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine, trifluoroacetate;

1-[4-({[4-(methyloxy)-2-pyridinyl]methyl}oxy)-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)phenyl]ethanone;
1-[4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)phenyl]ethanone, trifluoroacetate;
7-[2-({[4-(methyloxy)-2-pyridinyl]methyl}oxy)phenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine, trifluoroacetate;
1,1-dimethylethyl 7-[6-methyl-3-({[4-(methyloxy)-2-pyridinyl]methyl}oxy)-2-pyridinyl]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate;
7-(5-fluoro-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
7-(5-methyl-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
7-(5-(ethyloxy)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
7-(5-(methyloxy)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzonitrile
7-[2-{[(4-methyl-2-pyridinyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine;
7-(5-(1,1-dimethylethyl)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
7-(5-chloro-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
7-(3-{[(4-ethyl-2-pyridinyl)methyl]oxy}-6-methyl-2-pyridinyl)-2,3,4,5-tetrahydro-1H-3-benzazepine
7-(6-(1,1-dimethylethyl)-3-{[(4-methyl-2-pyridinyl)methyl]oxy}-2-pyridinyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
1-[4-{[(4-ethyl-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)phenyl]ethanone;
1-[4-({[4-(ethyloxy)-2-pyridinyl]methyl}oxy)-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)phenyl]ethanone;
1-[4-{[(4-{[2-(methyloxy)ethyl]oxy}-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)phenyl]ethanone;
7-{5-(methyloxy)-2-[(2-pyridinylmethyl)oxy]phenyl}-2,3,4,5-tetrahydro-1H-3-benzazepine;
1-[4-[(2-pyridinylmethyl)oxy]-3-(1,2,3,4-tetrahydro-7-isoquinolinyl)phenyl]ethanone;
7-{5-chloro-2-[(2-pyridinylmethyl)oxy]phenyl}-1,2,3,4-tetrahydroisoquinoline;
7-(6-chloro-3-{[(4-methyl-2-pyridinyl)methyl]oxy}-2-pyridinyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
7-(6-chloro-3-{[(4-methyl-2-pyridinyl)methyl]oxy}-2-pyridinyl)-1,2,3,4-tetrahydroisoquinoline;
1,1-dimethylethyl 5-{5-acetyl-2-[(2-pyridinylmethyl)oxy]phenyl}-1,3-dihydro-2H-isoindole-2-carboxylate;

1-[4-[(2-pyridinylmethyl)oxy]-3-(1,2,3,4-tetrahydro-6-isoquinolinyl)phenyl]ethanone; and
7-{2-(methyloxy)-6-[(2-pyrazinylmethyl)oxy]phenyl}-2,3,4,5-tetrahydro-1H-3-benzazepine, hydrochloride; or a salt thereof.

14. A compound which is selected from:
7-(3-{[(4-methyl-2-pyridinyl)methyl]oxy}-2-pyridinyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(2-(methyloxy)-6-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(4-(methyloxy)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
1-[4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)phenyl]ethanone;
1-[4-[(2-pyrazinylmethyl)oxy]-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)phenyl]ethanone;
7-(5-fluoro-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
7-[2-({[4-(methyloxy)-2-pyridinyl]methyl}oxy)phenyl]-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and
1-[4-[(2-pyridinylmethyl)oxy]-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)phenyl]ethanone; or a salt thereof.

15. A compound according to claim 14 which is:
7-(2-(methyloxy)-6-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
or a salt thereof.

16. A compound or a salt thereof according to any one of claims 1 to 15, wherein the salt is a pharmaceutically acceptable salt.

17. A compound or a salt thereof according to claim 16, wherein the salt is mesylate.

18. A pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 16 or 17, and one or more pharmaceutically acceptable carriers, diluents or excipients.

19. A pharmaceutical composition according to claim 18, wherein the composition is adapted for topical dermal administration.

20. A combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 16, or claim 17, together with one or more other therapeutically active agents.

21. A compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 16, or claim 17, for use in therapy.

22. A compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 16, or claim 17, for use in inhibiting spleen tyrosine kinase.

23. A compound or a pharmaceutically acceptable salt thereof as defined in claim 16, or claim 17, for use in the treatment of an autoimmune condition.

24. A compound or a pharmaceutically acceptable salt thereof for use according to claim 21, wherein the autoimmune condition is chronic idiopathic urticaria with and without auto-antibody status.

25. A compound or a pharmaceutically acceptable salt thereof for use according to claim 21, wherein the autoimmune condition is discoid (cutaneous) lupus.

26. A compound or a pharmaceutically acceptable salt thereof as defined in claim 16, or claim 17, for use in the treatment of cancer.

27. A compound or a pharmaceutically acceptable salt thereof as defined in claim 16, or claim 17, for use in the treatment of a disease associated with inappropriate mast cell activation.

28. A compound or a pharmaceutically acceptable salt thereof as defined in claim 16, or claim 17, for use in the treatment of an inflammatory disease and/or allergic disorder.

29. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 16, or claim 17, for the manufacture of a medicament for the treatment of an autoimmune condition.

30. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 16, or claim 17, for the manufacture of a medicament for the treatment of cancer.

31. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 16, or claim 17, for the manufacture of a medicament for the treatment of an inflammatory disease and/or allergic disorder.

32. A method of treating an autoimmune condition, which comprises administering in a human subject in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 16 or claim 17.

33. A method of treatment according to claim 32, wherein the autoimmune condition is chronic idiopathic urticaria with and without auto-antibody status.

34. A method of treatment according to claim 32, wherein the autoimmune condition is discoid (cutaneous) lupus.


35. A method of treating cancer which comprises administering to a human subject in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 16, or claim 17.

36. A method of treating a disease associated with inappropriate mast cell activation, which comprises administering to a human subject in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 16, or claim 17.

37. A method of treating an inflammatory disease and/or allergic disorder, which comprises administering to a human subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 16, or claim 17.

Claims


1. A compound of formula (I):



(I)

wherein:
X is CR_1 or N;
Y is CH, C or N;
R_1 is hydrogen, C_{1-6}alkoxy or C_{1-6}alkyl;
R_2 is hydrogen, C_{1-6}alkoxy, halo, -$C(O)C_{1-6}$alkyl, CN, Halo-C_{1-6}alkyl or $C(O)NR_4R_5$;
R_3 is hydrogen or C_{1-6}alkoxy;
R_4 is hydrogen or C_{1-6}alkyl:
R_5 is hydrogen or C_{1-6}alkyl and
m and n are integers each independently selected from 1 and 2; or
a salt thereof.

2. A compound according to claim 1, wherein the compound is a compound of formula (Ia):



(Ia)

wherein:
X is CR_1 or N;
Y is CH, C or N;
R_1 is hydrogen, C_{1-6}alkoxy or C_{1-6}alkyl;
R_2 is hydrogen, C_{1-6}alkoxy, halo or -$C(O)C_{1-6}$alkyl; and
m and n are integers each independently selected from 1 and 2; or
a salt thereof.

3. A compound or a salt thereof according to claim 1 or claim 2 wherein X is CR_1.

4. A compound or a salt thereof according to claim 3 wherein R_1 is methyl, methoxy or hydrogen.

5. A compound or a salt thereof according to any one of claims 1 to 4 wherein Y is C.

6. A compound or a salt thereof according to any one of claims 1 to 5 wherein R_2 is hydrogen, methoxy or $-C(O)CH_3$.

7. A compound or a salt thereof according to any one of claims 1 to 6 wherein R_3 is hydrogen or methoxy.

8. A compound or a salt thereof according to any one of claims 1 to 7 wherein m and n are both 2.

9. A compound which is selected from:
7-(3-{[(4-methyl-2-pyridinyl)methyl]oxy}-2-pyridinyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(2-(methyloxy)-6-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(4-(methyloxy)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
1-[4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)phenyl]ethanone;
1-[4-[(2-pyrazinylmethyl)oxy]-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)phenyl]ethanone;
7-(5-fluoro-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
7-[2-({[4-(methyloxy)-2-pyridinyl]methyl}oxy)phenyl]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
1-[4-[(2-pyridinylmethyl)oxy]-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)phenyl]ethanone;
7-(6-methyl-3-{[(4-methyl-2-pyridinyl)methyl]oxy}-2-pyridinyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(5-methyl-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
7-(2-(methyloxy)-6-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
7-(5-(ethyloxy)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;

7-{2-(methyloxy)-6-[(2-pyrazinylmethyl)oxy]phenyl}-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(1,2,3,4-tetrahydro-7-isoquinolinyl)benzonitrile;
7-[2-{[(4-methyl-2-pyridinyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydroisoquinoline;
7-(5-(methyloxy)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
7-(5-(1,1-dimethylethyl)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
7-{6-methyl-3-[(2-pyrazinylmethyl)oxy]-2-pyridinyl}-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(6-methyl-3-{[(4-methyl-2-pyridinyl)methyl]oxy}-2-pyridinyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-{5-(methyloxy)-2-[(2-pyrazinylmethyl)oxy]phenyl}-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-[5-(methyloxy)-2-({[4-(methyloxy)-2-pyridinyl]methyl}oxy)phenyl]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
1-[4-({[4-(methyloxy)-2-pyridinyl]methyl}oxy)-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)phenyl]ethanone;
7-[2-({[4-(methyloxy)-2-pyridinyl]methyl}oxy)phenyl]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(5-fluoro-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(5-methyl-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(5-(ethyloxy)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(5-(methyloxy)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)benzonitrile;
7-[2-{[(4-methyl-2-pyridinyl)methyl]oxy}-5-(trifluoromethyl)phenyl]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(5-(1,1-dimethylethyl)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(3-{[(4-ethyl-2-pyridinyl)methyl]oxy}-6-methyl-2-pyridinyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(6-(1,1-dimethylethyl)-3-{[(4-methyl-2-pyridinyl)methyl]oxy}-2-pyridinyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
1-[4-{[(4-ethyl-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)phenyl]ethanone;
1-[4-({[4-(ethyloxy)-2-pyridinyl]methyl}oxy)-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)phenyl]ethanone;

7-{5-(methyloxy)-2-[(2-pyridinylmethyl)oxy]phenyl}-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
1-[4-[(2-pyridinylmethyl)oxy]-3-(1,2,3,4-tetrahydro-7-isoquinolinyl)phenyl]ethanone;
N-methyl-4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)benzamide;
4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)benzamide;
N,*N*-dimethyl-4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(1,2,3,4-tetrahydro-7-isoquinolinyl)benzamide;
4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(1,2,3,4-tetrahydro-7-isoquinolinyl)benzamide;
7-(2,3-bis(methyloxy)-6-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
7-(2,3-bis(methyloxy)-6-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(5-chloro-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-{5-chloro-2-[(2-pyridinylmethyl)oxy]phenyl}-1,2,3,4-tetrahydroisoquinoline;
7-[6-methyl-3-({[4-(methyloxy)-2-pyridinyl]methyl}oxy)-2-pyridinyl]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(6-chloro-3-{[(4-methyl-2-pyridinyl)methyl]oxy}-2-pyridinyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(6-chloro-3-{[(4-methyl-2-pyridinyl)methyl]oxy}-2-pyridinyl)-1,2,3,4-tetrahydroisoquinoline;
1-[4-{[(4-{[2-(methyloxy)ethyl]oxy}-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)phenyl]ethanone;
1-{3-(2,3-dihydro-1*H*-isoindol-5-yl)-4-[(2-pyridinylmethyl)oxy]phenyl}ethanone; and
1-[4-[(2-pyridinylmethyl)oxy]-3-(1,2,3,4-tetrahydro-6-isoquinolinyl)phenyl]ethanone; or a salt thereof.

10. A compound which is selected from:
7-(3-{[(4-methyl-2-pyridinyl)methyl]oxy}-2-pyridinyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(2-(methyloxy)-6-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
7-(4-(methyloxy)-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
1-[4-{[(4-methyl-2-pyridinyl)methyl]oxy}-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)phenyl]ethanone;
1-[4-[(2-pyrazinylmethyl)oxy]-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)phenyl]ethanone;
7-(5-fluoro-2-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-1,2,3,4-tetrahydroisoquinoline;
7-[2-({[4-(methyloxy)-2-pyridinyl]methyl}oxy)phenyl]-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and

1-[4-[(2-pyridinylmethyl)oxy]-3-(2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)phenyl]ethanone; or a salt thereof.

11. A compound which is:
7-(2-(methyloxy)-6-{[(4-methyl-2-pyridinyl)methyl]oxy}phenyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine; or a salt thereof.

12. A compound or a salt thereof according to any one of claims 1 to 11, wherein the salt is a pharmaceutically acceptable salt.

13. A pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 12 and one or more pharmaceutically acceptable carriers, diluents or excipients.

14. A pharmaceutical composition according to claim 13, wherein the composition is adapted for topical dermal administration.

15. A combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 12, together with one or more other therapeutically active agents.

16. A compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 12, for use in therapy.

17. A compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 12, for use in inhibiting spleen tyrosine kinase.

18. A compound or a pharmaceutically acceptable salt thereof as defined in claim 12, for use in the treatment of an autoimmune condition.

19. A compound or a pharmaceutically acceptable salt thereof for use according to claim 18, wherein the autoimmune condition is chronic idiopathic urticaria with and without auto-antibody status.

20. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 12, for the manufacture of a medicament for the treatment of an autoimmune condition.